Paris, France and Manchester, UK – 19 May 2026 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces
Novacyt S.A. (AIM:NCYT) Full year trading update
Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
Novacyt S.A. (AIM: NCYT) London Vet Show: Launch of animal multiplex assays
Launch of new animal multiplex assays at London Vet Show Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs
Novacyt S.A. (LON:NCYT) Settlement of the dispute with the DHSC
Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the
Novacyt S.A. (AIM:NCYT) Directorate Changes and FY 23 results update
Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces changes to the Board of Directors.
Novacyt S.A. (AIM:NCYT) Update on Taiwan laboratory disposal
Paris, France, Eastleigh and Manchester, UK – 21 December 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an update to the
Novacyt S.A. (AIM:NCYT) Completion of acquisition of Yourgene Health plc
The acquisition adds scale and diversification to create a stronger global diagnostics business, with a complementary suite of genomic technologies and services
Yourgene Health PLC (AIM:YGEN) Rule 2.7 Announcement
RECOMMENDED CASH OFFER by Novacyt UK Holdings Limited (a wholly-owned subsidiary of Novacyt S.A.) for Yourgene Health plc to be effected by means of a Scheme of Arrangement under Part
Novacyt S.A. Final Results, Full year revenue and EBITDA
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Novacyt S.A. (AIM:NCYT) DHSC Claim update – Trial date listed
Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt
Novacyt S.A. (AIM:NCYT) Approval of genesig COVID-19 3G PCR test in UK
Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation
Novacyt S.A. (AIM:NCYT) UK Approval of genesig® SARS-CoV-2 Winterplex® 3G
A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV